Pure Global
NCT06414148

MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

A Phase II Open-Label, Multi-Centre Study of Minimal Residual Disease-Directed Consolidation With Epcoritamab or Epcoritamab-Lenalidomide-Rituximab Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma (EpLCART)
Peter MacCallum Cancer Centre, Australia·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Relapsed/Refractory Large B-cell Lymphoma
Drug/Device/Intervention
Epcoritamab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Peter MacCallum Cancer Centre, Australia
Location
Camperdown,Westmead,Herston,Melbourne,Melbourne,Murdoch, Australia
Timeline & enrollment
Phase
Phase 2
Start date
May 07, 2024
End date
May 01, 2028
Enrollment
40 participants
Primary outcome

The efficacy of Epcor-only (epcoritamab alone) or Epcor-R2 (epcoritamab, lenalidomide and rituximab) consolidation as assessed by conventional (Lugano 2014) response criteria at month 12 after the CART infusion

Summary

This is a Phase II open-label, two-arm randomised non-comparative, multi-centre study to
 evaluate the efficacy of Epcor-only (Epcoritamab alone) or Epcor-R2 (Epcoritamab,
 lenalidomide and rituximab) as consolidation post anti-CD19 CAR T-cell therapy for patients
 that have responded by conventional criteria but who are at high risk of progression by
 virtue of being Minimal Residual Disease (MRD) positive as determined by a Circulating Tumour
 DNA (ctDNA) assay.

ICD-10 classifications
Diffuse large B-cell lymphomaB-cell lymphoma, unspecifiedSmall cell B-cell lymphomaMediastinal (thymic) large B-cell lymphomaChronic lymphocytic leukaemia of B-cell type
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06414148
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06414148 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peter MacCallum Cancer Centre, Australia and is currently Not yet recruiting. The study focuses on Relapsed/Refractory Large B-cell Lymphoma. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.